(NasdaqGM:FINW), MURRAY, Utah, July 01, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), the parent company of FinWise Bank, today announced that it will report its second quarter 2025 results and host a conference call and webcast after the market close on Thursday, July 24, 2025. Conference Call Information The conference […]
(NYSE:SON), HARTSVILLE, S.C., July 01, 2025 (GLOBE NEWSWIRE) — Sonoco Products Company (“Sonoco” or the “Company”)(NYSE: SON), a global leader in high-value sustainable packaging, will announce second quarter 2025 results on Wednesday, July 23, 2025, after the market closes. The Company will host a conference call to discuss these results on Thursday, July 24, 2025,
(NYSE:WSO), MIAMI, July 01, 2025 (GLOBE NEWSWIRE) — Watsco, Inc.'s (NYSE: WSO) Board of Directors has declared a regular quarterly cash dividend of $3.00 on each outstanding share of its Common and Class B common stock payable on July 31, 2025 to shareholders of record at the close of business on July 16, 2025. Watsco
(NasdaqGM:NEXN), NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that during June 2025 the Company repurchased 800,000 Ordinary Shares at an average price of $10.45. As of June 30, 2025,
Active Ingredient Manufacturing Transfer to the U.S. Complete Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active
DougDeSchutter and Tom Carey to take on new responsibilities Broadridge Financial Solutions, Inc. (NYSE: BR), a global Fintech leader, today announced expanded roles for two senior members of its leadership team to support Broadridge's continued evolution to a platform company. The changes are effective as of July 1. Doug DeSchutter has been named President, Investor
Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be
— Expert dermatologist panel creates newatopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD's intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization through infection — Panel underscores unmet need for topical multi-target therapeutic such as investigational new drug candidate Zabalafin Hydrogel to meet
John Koudounis, President and CEO of Calamos, a leading alternatives manager, announced the launch of the Calamos Aksia Private Equity & Alternatives Fund (Ticker: CAPVX). The Fund is designed to provide investors with access to a diversified portfolio of private equity investments across buyouts, growth equity, and venture capital. CAPVX will focus on investing in
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target GlobeNewswire July 01, 2025 PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 'START' Study surpasses 50% enrollment.